Dendreon Interest Remains Extremely High
by Jon C. Ogg
247 Wall St.
Since Dendreon (DNDN) has gotten a bit of life this week, there have been numerous inquiries as to "Where is this stock going?" from stock investors.
There is obviously some hope by investors that the activists will be able to push the FDA into approving Provenge for late-stage prostate cancer. The fact that an activist group has started Provengenow.org probably says it all. It is not yet known who started Provengenow.org's web site because the registrar is actually "MyPrivateRegistration" if you look up the domain owner. This web site has actually become more full with more data even since yesterday. What is becoming more obvious is that Dendreon "may" find itself as winner because of "cancer patient activism" rather than investor activism. This activist group was also noted yesterday on CNBC and this helped the bullish scenario's fight yesterday.
Continue article at 247WallSt.com
RELATED READING:
- Dendreon's New Double-Twist
- Dendreon, the Day That Could Have Been and What to Expect Now
- Rantasorous Rx
___________________
247 Wall St.
Since Dendreon (DNDN) has gotten a bit of life this week, there have been numerous inquiries as to "Where is this stock going?" from stock investors. There is obviously some hope by investors that the activists will be able to push the FDA into approving Provenge for late-stage prostate cancer. The fact that an activist group has started Provengenow.org probably says it all. It is not yet known who started Provengenow.org's web site because the registrar is actually "MyPrivateRegistration" if you look up the domain owner. This web site has actually become more full with more data even since yesterday. What is becoming more obvious is that Dendreon "may" find itself as winner because of "cancer patient activism" rather than investor activism. This activist group was also noted yesterday on CNBC and this helped the bullish scenario's fight yesterday.
Continue article at 247WallSt.com
RELATED READING:
- Dendreon's New Double-Twist
- Dendreon, the Day That Could Have Been and What to Expect Now
- Rantasorous Rx
___________________
posted by Nico at
11:56 AM
1 Comments:
Even if the vaccine is approved, I doubt any third party payer, Medicare included, will reimburse for it absent data showing extended survival. Look at what happened with Thin-Prep and how long it took Cytyc to get reimbursements for it--and there was no doubt about its efficacy.
Post a Comment
Subscribe to Post Comments [Atom]
<< Home